ストックスクリーナーアプリを入手
4.65
3.12%
-0.15
アフターアワーズ：
4.64
-0.01
-0.22%
前日終値:
$4.80
開ける：
$4.87
24時間の取引高:
15,639
Relative Volume:
0.29
時価総額：
$200.07M
収益：
$4.71M
当期純損益:
$-46.77M
株価収益率:
-2.7692
EPS:
-1.6792
ネットキャッシュフロー:
$-60.34M
1週間 パフォーマンス:
-4.52%
1か月 パフォーマンス:
+0.65%
6か月 パフォーマンス:
-39.77%
1年 パフォーマンス:
-41.44%
1日の値動き範囲:
$4.6269
$4.87
1週間の範囲:
$4.6269
$4.93
52週間の値動き範囲:
$4.345
$11.87
Nyxoah Sa Stock (NYXH) Company Profile
NYXH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
4.65 | 206.53M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
561.89 | 197.40B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
194.70 | 55.76B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
79.50 | 38.93B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
242.55 | 35.90B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
WST
West Pharmaceutical Services Inc
|
268.66 | 19.36B | 2.96B | 487.70M | 344.00M | 6.6758 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-07-31 | 開始されました | H.C. Wainwright | Buy |
| 2023-07-19 | 開始されました | Robert W. Baird | Neutral |
| 2022-04-21 | 開始されました | Oppenheimer | Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Peer Perform |
| 2021-12-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-07-28 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Nyxoah Sa (NYXH) 最新ニュース
Nyxoah Launches New OSA Therapy | Patient-Centric Breakthrough - Precedence Research
Nyxoah announces commercial launch of Genio system in the Netherlands - TipRanks
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands - GlobeNewswire
Nyxoah price target lowered to EUR 5 from EUR 7 at Baird - TipRanks
Nyxoah (NASDAQ:NYXH) Trading Down 2.9%Here's What Happened - MarketBeat
Nyxoah (NASDAQ:NYXH) Trading Down 2.9% – Here’s What Happened - Defense World
Nyxoah announces shareholding changes as Robert Taub surpasses 10% threshold - MSN
Critical Analysis: Nyxoah (NASDAQ:NYXH) & P3 Health Partners (NASDAQ:PIII) - Defense World
Nyxoah Announces Shareholding Changes as Robert Taub Surpasses 10% Threshold - TipRanks
How Nyxoah SA (5YI) stock compares with tech leadersWeekly Stock Analysis & Community Verified Trade Signals - Newser
Will Nyxoah SA stock outperform international peersIPO Watch & Accurate Technical Buy Alerts - Newser
Is Nyxoah SA stock a buy for dividend growthJuly 2025 Levels & Risk Controlled Daily Plans - Newser
Will Nyxoah SA (5YI) stock remain on Wall Street radar2025 Institutional Moves & Reliable Breakout Forecasts - Newser
Nyxoah (NYXH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Publication relating to transparency notifications - marketscreener.com
Can Nyxoah SA (5YI) stock sustain institutional flowsJuly 2025 Intraday Action & Daily Chart Pattern Signals - Newser
What MACD trends signal for Nyxoah SA (5YI) stock2025 Dividend Review & Verified Entry Point Signals - Newser
Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System - sharewise.com
Nyxoah’s Genio Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule - Sleep Review
Why Nyxoah SA stock is recommended by analystsTrade Entry Report & AI Driven Stock Price Forecasts - moha.gov.vn
Why The Narrative Around Nyxoah Is Shifting Amid Fresh Developments and Analyst Caution - Yahoo Finance
How Nyxoah SA stock performs in high volatility marketsRecession Risk & Trade Opportunity Analysis Reports - moha.gov.vn
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Nyxoah receives Medicare reimbursement increases for Genio - MSN
Nyxoah (NASDAQ: NYXH) schedules webcast fireside chat at Piper Sandler healthcare conference - Stock Titan
Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy - MSN
Nyxoah S.A. (NASDAQ:NYXH) Q3 2025 Earnings Call Transcript - MSN
Nyxoah’s Genio therapy gets significant 2026 Medicare reimbursement increases under final CMS rule - MSN
Nyxoah Notes Higher US Reimbursements for Genio Implant Procedures in 2026 - marketscreener.com
01 Communique (TSXV: ONE) teams with Turnium to expand IronCAP X quantum-safe email - Stock Titan
Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule - Yahoo Finance
Nyxoah SA (NYXH) Q3 2025 Earnings Call Highlights: Strong US Launch and Strategic Expansion ... By GuruFocus - Investing.com Canada
Will Supply Chain Issues Impact Indian Toners Developers Limiteds PerformanceExit Strategy Tips & High Profit Investment Ideas - earlytimes.in
Will Nyxoah SA (5YI) stock extend growth storyCPI Data & Accurate Technical Buy Alerts - newser.com
Can Nyxoah SA stock sustain free cash flow growth2025 Key Lessons & Free Real-Time Market Sentiment Alerts - newser.com
Why Nyxoah SA (5YI) stock attracts wealthy investorsIndex Update & Consistent Growth Equity Picks - newser.com
Nyxoah (NASDAQ: NYXH) Reports 43,026,460 Voting Rights and Share Capital Update - Stock Titan
Why Nyxoah SA stock is seen as undervaluedJuly 2025 Decliners & Low Drawdown Investment Strategies - newser.com
Can Nyxoah SA stock sustain market leadershipJuly 2025 Market Mood & AI Forecasted Stock Moves - newser.com
Information on the total number of voting rights and shares - GlobeNewswire
Should I buy Nyxoah SA (5YI) stock before earnings seasonWeekly Risk Report & Daily Chart Pattern Signals - newser.com
How Nyxoah SA (5YI) stock trades under stagflation2025 EndofYear Setup & Safe Capital Investment Plans - newser.com
How Nyxoah SA (5YI) stock compares with market leaders2025 Support & Resistance & Momentum Based Trading Signals - newser.com
How high can Nyxoah SA stock go2025 Dividend Review & Weekly Setup with ROI Potential - newser.com
Heatmap analysis for Nyxoah SA and competitorsJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Latham DQ'd From Sleep Apnea Device Co.'s Patent Fight - Law360
How Nyxoah SA (5YI) stock trades pre earningsJuly 2025 Final Week & Verified Momentum Stock Watchlist - newser.com
Nyxoah Sa (NYXH) 財務データ
収益
当期純利益
現金流量
EPS
1.14%
0.54%
大文字化:
|
ボリューム (24 時間):